Matinas BioPharma (MTNB) 10-Q 10 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 05, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-38022
Entity Registrant Name	MATINAS BIOPHARMA HOLDINGS, INC.
Entity Central Index Key	0001582554
Entity Tax Identification Number	46-3011414
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1545 Route 206 South
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Bedminster
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07921
City Area Code	908
Local Phone Number	484-8805
Title of 12(b) Security	Common Stock
Trading Symbol	MTNB
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		214,741,422

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 30,352,359	$ 12,432,481
Marketable securities	29,490,430	46,246,573
Restricted cash – security deposits	136,000	136,000
Prepaid expenses and other current assets	960,422	2,739,791
Total current assets	60,939,211	61,554,845
Non-current assets:
Leasehold improvements and equipment - net	1,406,748	1,523,950
Operating lease right-of-use assets - net	3,034,155	3,276,639
Finance lease right-of-use assets - net	37,350	58,007
In-process research and development	3,017,377	3,017,377
Goodwill	1,336,488	1,336,488
Restricted cash - security deposit	200,000	200,000
Total non-current assets	9,032,118	9,412,461
Total assets	69,971,329	70,967,306
Current liabilities:
Accounts payable	450,461	349,941
Accrued expenses	2,762,736	2,795,329
Operating lease liabilities - current	351,257	391,498
Financing lease liabilities - current	26,870	30,853
Total current liabilities	3,591,324	3,567,621
Non-current liabilities:
Deferred tax liability	341,265	341,265
Operating lease liabilities - net of current portion	3,123,482	3,304,063
Financing lease liabilities - net of current portion	11,508	23,660
Total non-current liabilities	3,476,255	3,668,988
Total liabilities	7,067,579	7,236,609
Stockholders’ equity:
Series B Convertible preferred stock, stated value $1,000 per share, 8,000 shares authorized as of June 30, 2021 and December 31, 2020; 0 and 4,361 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively		3,797,705
Common stock par value $0.0001 per share, 500,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 214,627,522 and 200,113,431 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	21,462	20,010
Additional paid-in capital	180,929,263	167,192,003
Accumulated deficit	(118,098,218)	(107,507,193)
Accumulated other comprehensive income	51,243	228,172
Total stockholders’ equity	62,903,750	63,730,697
Total liabilities and stockholders’ equity	$ 69,971,329	$ 70,967,306

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Series B Convertible preferred stock, par value	$ 1,000	$ 1,000
Series B Convertible preferred stock, shares authorized	8,000	8,000
Series B Convertible preferred stock, shares issued	0	4,361
Series B Convertible preferred stock, shares outstanding	0	4,361
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	214,627,522	200,113,431
Common stock, shares outstanding	214,627,522	200,113,431

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Research and development			$ 33,333
Costs and expenses:
Research and development	2,480,764	3,410,237	5,722,196	7,497,120
General and administrative	2,308,926	2,356,310	5,453,936	4,615,941
Total costs and expenses	4,789,690	5,766,547	11,176,132	12,113,061
Loss from operations	(4,789,690)	(5,766,547)	(11,142,799)	(12,113,061)
Sale of New Jersey net operating loss & tax credits			1,328,470	1,073,289
Other income, net	(1,415)	156,000	66,904	383,327
Net loss	(4,791,105)	(5,610,547)	(9,747,425)	(10,656,445)
Preferred stock series B accumulated dividends	(184,899)	(177,092)	(395,799)	(347,792)
Net loss attributable to common shareholders	$ (4,976,004)	$ (5,787,639)	$ (10,143,224)	$ (11,004,237)
Net loss available for common shareholders per share - basic and diluted	$ (0.02)	$ (0.03)	$ (0.05)	$ (0.06)
Weighted average common shares outstanding - basic and diluted	205,215,259	197,601,500	204,547,251	194,636,326
Other comprehensive (loss)/income, net of tax
Net unrealized (loss)/gain on securities available-for-sale	$ (85,163)	$ (41,954)	$ (176,929)	$ 481,303
Reclassifications to net loss		(2,708)		(2,719)
Other comprehensive (loss)/income, net of tax	(85,163)	(44,662)	(176,929)	478,584
Comprehensive loss attributable to shareholders	$ (4,876,268)	$ (5,655,209)	$ (9,924,354)	$ (10,177,861)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Redeemable Convertible Preferred Stock B [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 3,985,805	$ 16,315	$ 113,427,897	$ (84,377,555)	$ (880)	$ 33,051,582
Balance, shares at Dec. 31, 2019	4,577	163,156,984
Stock-based compensation			2,218,530			2,218,530
Issuance of common stock as compensation for services		$ 25	188,104			188,129
Issuance of common stock as compensation for services, shares		246,987
Issuance of common stock in exchange for preferred stock	$ (21,771)	$ 5	21,766
Issuance of common stock in exchange for preferred stock, shares	(25)	50,000
Issuance of common stock in public offering, net of stock issuance costs ($3,298,790)		$ 3,226	46,700,984			46,704,210
Issuance of common stock in public offering, net of stock issuance costs, shares		32,260,000
Issuance of common stock from the exercise of Common Stock Options		$ 6	42,494			42,500
Issuance of common stock from the exercise of Common Stock Options, shares		56,517
Issuance of common stock from the exercise of Warrants		$ 172	797,409			797,581
Issuance of common stock from the exercise of Warrants, shares		1,737,389
Stock dividend		$ 137	682,663	(682,800)
Stock dividend, shares		1,365,600
Other comprehensive loss					478,584	478,584
Net loss				(10,656,445)		(10,656,445)
Ending balance, value at Jun. 30, 2020	$ 3,964,034	$ 19,886	164,079,847	(95,716,800)	477,704	72,824,671
Balance, shares at Jun. 30, 2020	4,552	198,873,477
Beginning balance, value at Mar. 31, 2020	$ 3,964,034	$ 19,719	162,520,461	(89,423,453)	522,366	77,603,127
Balance, shares at Mar. 31, 2020	4,552	197,202,938
Stock-based compensation			850,879			850,879
Issuance of common stock as compensation for services		$ 2	15,872			15,874
Issuance of common stock as compensation for services, shares		20,537
Stock issuance cost			10,000			10,000
Issuance of common stock from the exercise of Warrants		$ 28	(28)
Issuance of common stock from the exercise of Warrants, shares		284,402
Stock dividend		$ 137	682,663	(682,800)
Stock dividend, shares		1,365,600
Other comprehensive loss					(44,662)	(44,662)
Net loss				(5,610,547)		(5,610,547)
Ending balance, value at Jun. 30, 2020	$ 3,964,034	$ 19,886	164,079,847	(95,716,800)	477,704	72,824,671
Balance, shares at Jun. 30, 2020	4,552	198,873,477
Beginning balance, value at Dec. 31, 2020	$ 3,797,705	$ 20,010	167,192,003	(107,507,193)	228,172	63,730,697
Balance, shares at Dec. 31, 2020	4,361	200,113,431
Stock-based compensation			2,100,402			2,100,402
Issuance of common stock as compensation for services		$ 2	15,874			15,876
Issuance of common stock as compensation for services, shares		17,804
Issuance of common stock in exchange for preferred stock	$ (3,797,705)	$ 873	3,796,832
Issuance of common stock in exchange for preferred stock, shares	(4,361)	8,722,000
Issuance of common stock in public offering, net of stock issuance costs ($172,592)		$ 302	5,580,169			5,580,471
Issuance of common stock in public offering, net of stock issuance costs, shares		3,023,147
Issuance of common stock from the exercise of Common Stock Options		$ 106	1,400,552			1,400,658
Issuance of common stock from the exercise of Common Stock Options, shares		1,062,883
Issuance of common stock from the exercise of Warrants
Issuance of common stock from the exercise of Warrants, shares		1,057
Stock dividend		$ 169	843,431	(843,600)
Stock dividend, shares		1,687,200
Other comprehensive loss					(176,929)	(176,929)
Net loss				(9,747,425)		(9,747,425)
Ending balance, value at Jun. 30, 2021		$ 21,462	180,929,263	(118,098,218)	51,243	62,903,750
Balance, shares at Jun. 30, 2021		214,627,522
Beginning balance, value at Mar. 31, 2021	$ 3,673,176	$ 20,427	175,189,608	(112,463,513)	136,406	66,556,104
Balance, shares at Mar. 31, 2021	4,218	204,283,972
Stock-based compensation			1,027,345			1,027,345
Issuance of common stock as compensation for services		$ 1	7,937			7,938
Issuance of common stock as compensation for services, shares		10,244
Issuance of common stock in exchange for preferred stock	$ (3,673,176)	$ 844	3,672,332
Issuance of common stock in exchange for preferred stock, shares	(4,218)	8,436,000
Issuance of common stock from the exercise of Common Stock Options		$ 21	188,610			188,631
Issuance of common stock from the exercise of Common Stock Options, shares		210,106
Stock dividend		$ 169	843,431	(843,600)
Stock dividend, shares		1,687,200
Other comprehensive loss					(85,163)	(85,163)
Net loss				(4,791,105)		(4,791,105)
Ending balance, value at Jun. 30, 2021		$ 21,462	$ 180,929,263	$ (118,098,218)	$ 51,243	$ 62,903,750
Balance, shares at Jun. 30, 2021		214,627,522

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Common Stock [Member]
Stock issuance cost	$ 172,592	$ 3,298,790

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (9,747,425)	$ (10,656,445)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	117,202	115,433
Stock based compensation expense	2,156,941	2,391,694
Amortization of operating lease right-of-use assets	242,485	237,909
Amortization of finance lease right-of-use assets	20,656	41,678
Amortization of bond discount	108,562
Changes in operating assets and liabilities:
Operating lease liabilities	(220,822)	(200,762)
Prepaid expenses and other current assets	1,738,706	861,530
Accounts payable	100,520	(184,733)
Accrued expenses and other liabilities	(32,593)	(439,630)
Net cash used in operating activities	(5,515,768)	(7,833,326)
Cash flows from investing activities:
Purchase of marketable securities	(7,129,348)	(67,670,491)
Proceeds from sales of marketable securities	23,600,000	20,700,000
Purchases of leasehold improvements and equipment		(5,749)
Net cash provided by/(used in) investing activities	16,470,652	(46,976,240)
Cash flows from financing activities:
Net proceeds from public offering of common stock	5,580,471	46,639,210
Proceeds from exercise of warrants		797,581
Proceeds from exercise of options	1,400,658	42,500
Payments of capital lease liability - principal	(16,135)	(36,235)
Net cash provided by financing activities	6,964,994	47,443,056
Net increase/(decrease) in cash, cash equivalents and restricted cash	17,919,878	(7,366,510)
Cash, cash equivalents and restricted cash at beginning of period	12,768,481	22,756,438
Cash, cash equivalents and restricted cash at end of period	30,688,359	15,389,928
Supplemental non-cash financing and investing activities:
Unrealized (loss)/gains on securities for sale	(176,929)	478,584
Preferred stock conversion into common stock - Series B	3,797,705	21,771
Unearned restricted stock grants	27,858	73,490
Cashless exercise of warrants		441,189
Stock dividends issued	843,600	682,800
Deferred financing costs included in accrued expenses and other liabilities		$ 65,000

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Description of Business	Note 1 – Description of Business Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma”, “the Company” or “we” or “our” or “us”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.

Liquidity and Plan of Operation

Liquidity and Plan of Operations	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Plan of Operations	Note 2 – Liquidity and Plan of Operations The Company has experienced net losses and negative cash flows from operations each period since its inception. Through June 30, 2021, the Company had an accumulated deficit of approximately $ 118.1 9.7 10.7 The Company has been engaged in developing LYPDISO (formerly MAT9001) as well as its lipid nanocrystal (“LNC”) platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501, since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from product sales, and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability. Assuming the Company obtains Food and Drug Administration (“FDA”) approval for one or more of its product candidates, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing. To continue to fund operations, during January 2021, the Company sold 3,023,147 5.6 As of June 30, 2021, the Company had cash and cash equivalents of approximately $ 30.4 29.5 0.3

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The Company has prepared its condensed consolidated financial statements following the requirements of the SEC for interim reporting. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The Company’s significant accounting policies are described in Note 3 within the Company’s Notes to Consolidated Financial Statements included in the Company’s 2020 Form 10-K. COVID-19 In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, and has and may continue to cause economic downturns. The Company has been actively monitoring the impact of COVID-19. The financial results for the three and six months ended June 30, 2021 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of COVID-19 on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.

Cash, Cash Equivalents, Restric

Cash, Cash Equivalents, Restricted Cash and Marketable Securities	6 Months Ended
	Jun. 30, 2021
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, Restricted Cash and Marketable Securities	Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date. Cash, Cash Equivalents and Restricted Cash The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheets to the total of the amounts in the Condensed Consolidated Statements of Cash Flows as of June 30, 2021, December 31, 2020, June 30, 2020 and December 31, 2019: Schedule of Cash, Cash Equivalents and Restricted Cash June 30, December 31, June 30, December 31, Cash and cash equivalents $ 30,352 $ 12,432 $ 14,904 $ 22,170 Restricted cash included in current/long term assets 336 336 486 586 Cash, cash equivalents and restricted cash in the statement of cash flows $ 30,688 $ 12,768 $ 15,390 $ 22,756 Marketable Securities The Company has classified its investments in marketable securities as available-for-sale and as a current asset. The Company’s investments in marketable securities are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Unrealized losses and gains are classified as other comprehensive (loss)/income and costs are determined on a specific identification basis. Realized gains and losses from our marketable securities are recorded in other income, net. For the three and six months ended June 30, 2021, the Company recorded unrealized losses of approximately $ 85 177 42 481 51 228 The following tables summarizes the Company’s marketable securities as of June 30, 2021: Summary of Marketable Securities Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value U.S. Treasury Bonds $ 10,453 $ 29 $ - $ 10,482 U.S. Government Notes 10,624 31 (1 ) 10,654 Corporate Debt Securities 7,087 - (9 ) 7,078 State and Municipal Bonds 1,275 1 - 1,276 Total marketable securities $ 29,439 $ 61 $ (10 ) $ 29,490 Maturities of debt securities classified as available-for-sale were as follows at June 30, 2021: Schedule of Maturities of Debt Securities Available-for-sale Accrued Net Carrying Fair Value Interest Amount Due within one year $ 21,851 $ 122 $ 21,973 Due after one year through five years 7,639 25 7,664 $ 29,490 $ 147 $ 29,637 The following tables summarizes the Company’s marketable securities for the year ended December 31, 2020 consisted of the following: Summary of Marketable Securities Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value U.S. Treasury Bonds $ 18,293 $ 136 $ - $ 18,429 U.S. Government Notes 22,148 82 - 22,230 Corporate Debt Securities 4,303 3 - 4,306 State and Municipal Bonds 1,275 7 - 1,282 Total marketable securities $ 46,019 $ 228 $ - $ 46,247 Maturities of debt securities classified as available-for-sale were as follows at December 31, 2020: Schedule of Maturities of Debt Securities Available-for-sale Accrued Net Carrying Fair Value Interest Amount Due within one year $ 31,438 $ 164 $ 31,602 Due after one year through five years 14,809 36 14,845 $ 46,247 $ 200 $ 46,447

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 5 - Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of certain cash and cash equivalents, current portion of restricted cash, marketable securities, prepaid expenses and other current assets, accounts payable, current portion of lease liability and accrued expenses approximate fair value due to the short-term nature of these instruments. A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Schedule of Fair Value Measurement of Assets and Liabilities Fair Value Hierarchy June 30, 2021 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Treasury Bonds $ 10,482 $ 10,482 $ - $ - U.S. Government Notes 10,654 - 10,654 - Corporate Debt Securities 7,078 - 7,078 - State and Municipal Bonds 1,276 - 1,276 - Total $ 29,490 $ 10,482 $ 19,008 $ - Fair Value Hierarchy December 31, 2020 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Treasury Bonds $ 18,429 $ 18,429 $ - $ - U.S. Government Notes 22,230 - 22,230 - Corporate Debt Securities 4,306 - 4,306 - State and Municipal Bonds 1,282 - 1,282 - Total $ 46,247 $ 18,429 $ 27,818 $ - U.S. treasury bonds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets in active markets. Marketable securities consisting of U.S. government notes, corporate debt securities and state and municipal bonds are classified as Level 2 and are valued using quoted market prices in markets that are not active.

Leasehold Improvements and Equi

Leasehold Improvements and Equipment	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Leasehold Improvements and Equipment	Note 6 – Leasehold Improvements and Equipment Leasehold improvements and equipment, summarized by major category, consist of the following as of June 30, 2021 and December 31, 2020: Schedule of Leasehold Improvements and Equipment June 30, 2021 December 31, 2020 Lab equipment $ 1,443 $ 1,443 Leasehold improvements 878 878 Total 2,321 2,321 Less: accumulated depreciation and amortization 914 797 Leasehold improvements and equipment, net $ 1,407 $ 1,524 Depreciation and amortization expense for the three and six months ended June 30, 2021 was approximately $ 59 117 58 115

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Accrued Expenses and Other Liabilities	Note 7 – Accrued Expenses and Other Liabilities Accrued Expenses, summarized by major category, as of June 30, 2021 and December 31, 2020 consist of the following: Schedule of Accrued Expenses June 30, 2021 December 31, 2020 Payroll and incentives $ 619 $ 1,094 General and administrative expenses 249 280 Research and development expenses 1,055 778 Deferred revenue and other deferred liabilities * 840 643 Total $ 2,763 $ 2,795 * At June 30, 2021, there was an approximately $ 807 33 577 67

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Leases	Note 8 – Leases The Company has various lease agreements with terms up to 10 Some leases include purchase, termination or extension options for one or more years. Operating lease obligations On November 1, 2013, the Company entered into a 7 13,000 14,000 On September 23, 2020, the Company entered into an amendment to the Bedminster lease. Pursuant to the amendment, the Company leased an additional 3,034 seven years seven-year 1.8 The assets and liabilities from operating and finance leases are recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company’s operating leases did not provide an implicit rate that can readily be determined. Therefore, the Company uses a discount rate based on its incremental borrowing rate, which is determined using the average of borrowing rates explicitly stated in the Company’s finance leases. The Company incurred lease expense for its operating leases of approximately $ 204 407 203 407 116 243 120 238 The Company incurred interest expense on its finance leases of approximately $ 1 2 2 4 9 21 19 42 The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases, excluding the Expansion Premises which the Company had not taken control of as of June 30, 2021, and finance leases as of June 30, 2021: Schedule of Maturity of Operating and Finance Leases Liabilities Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities Remainder of 2021 $ 314 $ 17 2022 645 19 2023 677 2 2024 710 - 2025 745 - 2026 - - Thereafter 1,458 - Total undiscounted operating lease payments $ 4,549 $ 38 Less: Imputed interest 1,074 - Present value of operating lease liabilities $ 3,475 $ 38 Weighted average remaining lease term in years 6.3 1.3 Weighted average discount rate 8.4 % 8.0 % The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases, excluding the Expansion Premises which the Company had not taken control of as of December 31, 2020, and finance leases as of December 31, 2020: Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities 2021 $ 685 $ 34 2022 645 19 2023 677 2 2024 710 - 2025 745 - Thereafter 1,458 - Total undiscounted operating lease payments $ 4,920 $ 55 Less: Imputed interest 1,224 - Present value of operating lease liabilities $ 3,696 $ 55 Weighted average remaining lease term in years 6.7 1.7 Weighted average discount rate 8.4 % 8.1 %

Collaboration Agreements, Licen

Collaboration Agreements, Licenses and Other Research and Development Agreements	6 Months Ended
	Jun. 30, 2021
Research and Development [Abstract]
Collaboration Agreements, Licenses and Other Research and Development Agreements	Note 9 - Collaboration Agreements, Licenses and Other Research and Development Agreements Cystic Fibrosis Foundation Therapeutics Development Award On November 19, 2020, the Company entered into an award agreement (the “CFF Agreement”) with the CFF, pursuant to which it received a Therapeutics Development Award of up to $ 4.2 484,249 During the three and six months ended June 30, 2021, the Company recognized approximately $ 547 971 807 650 577 Genentech Feasibility Study Agreement On December 12, 2019, the Company entered into a feasibility study agreement (the “Genentech Agreement”) with Genentech, Inc. (“Genentech”). This feasibility study agreement involves the development of oral formulations using the Company’s LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Under the terms of the Genentech Agreement, Genentech shall pay the Company a total of $100 thousand for developing oral formulations of three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement. 100 33

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 10 – Income Taxes Sale of net operating losses (NOLs) & tax credits The Company recognized approximately $ 1.3 1.1

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Stockholders’ Equity	Note 11 – Stockholders’ Equity Common Stock For the six months ended June 30, 2021, the Company sold 3,023,147 1.90 5.8 5.6 On January 14, 2020, the Company closed an underwritten public offering of 32.3 million shares of its common stock at a purchase price of $ 1.55 per share. The Company generated gross proceeds of approximately $ 50.0 million and net proceeds of approximately $ 46.6 million, after deducting underwriting discounts and commissions and other estimated offering expenses. Preferred Stock In connection with a public offering of Series B Preferred Stock, on June 19, 2018, the Company filed the Series B Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series B Preferred Stock. Pursuant to the Series B Certificate of Designation, the Company designated 8,000 2,000 8,436,000 0 4,361 Dividends (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021. 1,687,200 1,365,600 Warrants The Company has issued two types of warrants: (i) investor warrants and (ii) placement agent warrants. All warrants are exercisable immediately upon issuance and have a five-year term. The warrants may be exercised at any time in whole or in part upon payment of the applicable exercise price until expiration. No fractional shares will be issued upon the exercise of the warrants. The exercise price and the number of shares purchasable upon the exercise of the investor warrants are subject to adjustment upon the occurrence of certain events, which include stock dividends, stock splits, combinations and reclassifications of the Company’s capital stock or other similar changes to the equity structure of the Company. As of June 30, 2021, the Company had outstanding warrants to purchase an aggregate of 1,325,810 0.50 0.75 Summary of Shareholders Equity Warrants Outstanding Shares Outstanding at December 31, 2019 5,397 Issued - Exercised (2,576 ) Tendered - Expired (1,493 ) Outstanding at December 31, 2020 1,328 * Outstanding at December 31, 2020 1,328 * Issued - Exercised (2 ) ** Tendered - Expired - Outstanding at June 30, 2021 1,326 *** * Weighted average exercise price for outstanding warrants is $ 0.55 ** Converted into approximately 1 thousand *** Weighted average exercise price for outstanding warrants is $ 0.54 Basic and diluted net loss per common share During the three and six months ended June 30, 2021 and 2020, diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion of preferred stock, would have an anti-dilutive effect. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common shareholders because including them would have been anti-dilutive for the three and six months ended June 30, 2021 and 2020: Schedule of Anti-Diluted Securities Excluded FromComputation of Earning Per Share As of June 30, 2021 2020 Stock options 22,162 22,317 Preferred Stock and accrued dividend upon conversion - 9,104 Warrants 1,326 1,328 Total 23,488 32,749

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2021
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income	Note 12 – Accumulated Other Comprehensive Income The following table summarizes the changes in accumulated other comprehensive income by components during the three months ended June 30, 2021 and 2020: Schedule of Components of Accumulated Other Comprehensive Income Net Unrealized (Losses)/Gains on Available-for-Sale Securities Accumulated Other Comprehensive Balance, December 31, 2020 $ 228 $ 228 Net unrealized loss on securities available-for-sale (177 ) (177 ) Reclassifications to net loss - - Net current period other comprehensive loss (177 ) (177 ) Balance, June 30, 2021 $ 51 $ 51 Balance, December 31, 2019 $ (1 ) $ (1 ) Net unrealized gain on securities available-for-sale 482 482 Reclassifications to net loss (3 ) (3 ) Net current period other comprehensive income 479 479 Balance, June 30, 2020 $ 478 $ 478 All components of accumulated other comprehensive income are net of tax.

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Note 13 – Stock-based Compensation The Company’s Amended and Restated 2013 Equity Compensation Plan (the “Plan”) provides for the granting of incentive stock options, nonqualified stock options, restricted stock units, performance units, and stock purchase rights. There were no significant modifications to the Plan during the six months ended June 30, 2021 and 2020. With the approval of the Board of Directors and a majority of shareholders, effective May 8, 2014, the Plan was amended and restated to provide for an automatic increase in the number of shares of common stock available for issuance under the Plan each January, commencing January 1, 2015, in an amount up to four percent ( 4 The following table contains information about the Company’s stock plan at June 30, 2021: Schedule of Equity Compensation Plan by Arrangements Awards Awards Awards 2013 Equity Compensation Plan 36,952 * 27,127 ** 9,825 * Increased by 8,005 4 ** Includes both restricted stock grants and option grants The Company recognized stock-based compensation expense (options and restricted share grants) in its condensed consolidated statements of operations as follows: Schedule of Recognized Stock-Based Compensation Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Research and Development $ 460 $ 358 $ 945 $ 1,180 General and Administrative 596 587 1,212 1,212 Total $ 1,056 $ 945 $ 2,157 $ 2,392 As of June 30, 2021, total compensation costs related to unvested awards not yet recognized was approximately $ 9.4 2.8 Stock Options The following table summarizes the activity for Company’ stock options for the three months ended June 30, 2021: Schedule of Stock Option Activity Stock Options Outstanding at January 1, 2021 22,551 Granted 4,697 Exercised (1,063) Forfeited (2,681) Cancelled - Expired (1,341) Outstanding at June 30, 2021 22,163 Restricted Stock Awards During the six months ended June 30, 2021 and 2020, the Company granted restricted stock awards for 18 247 28 57 93 173 28 100,000 0.3

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The Company has prepared its condensed consolidated financial statements following the requirements of the SEC for interim reporting. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The Company’s significant accounting policies are described in Note 3 within the Company’s Notes to Consolidated Financial Statements included in the Company’s 2020 Form 10-K.
COVID-19	COVID-19 In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, and has and may continue to cause economic downturns. The Company has been actively monitoring the impact of COVID-19. The financial results for the three and six months ended June 30, 2021 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of COVID-19 on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.

Cash, Cash Equivalents, Restr_2

Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2021
Cash and Cash Equivalents [Abstract]
Schedule of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheets to the total of the amounts in the Condensed Consolidated Statements of Cash Flows as of June 30, 2021, December 31, 2020, June 30, 2020 and December 31, 2019: Schedule of Cash, Cash Equivalents and Restricted Cash June 30, December 31, June 30, December 31, Cash and cash equivalents $ 30,352 $ 12,432 $ 14,904 $ 22,170 Restricted cash included in current/long term assets 336 336 486 586 Cash, cash equivalents and restricted cash in the statement of cash flows $ 30,688 $ 12,768 $ 15,390 $ 22,756
Summary of Marketable Securities	The following tables summarizes the Company’s marketable securities as of June 30, 2021: Summary of Marketable Securities Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value U.S. Treasury Bonds $ 10,453 $ 29 $ - $ 10,482 U.S. Government Notes 10,624 31 (1 ) 10,654 Corporate Debt Securities 7,087 - (9 ) 7,078 State and Municipal Bonds 1,275 1 - 1,276 Total marketable securities $ 29,439 $ 61 $ (10 ) $ 29,490
Schedule of Maturities of Debt Securities Available-for-sale	Maturities of debt securities classified as available-for-sale were as follows at June 30, 2021: Schedule of Maturities of Debt Securities Available-for-sale Accrued Net Carrying Fair Value Interest Amount Due within one year $ 21,851 $ 122 $ 21,973 Due after one year through five years 7,639 25 7,664 $ 29,490 $ 147 $ 29,637
Summary of Marketable Securities	The following tables summarizes the Company’s marketable securities for the year ended December 31, 2020 consisted of the following: Summary of Marketable Securities Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value U.S. Treasury Bonds $ 18,293 $ 136 $ - $ 18,429 U.S. Government Notes 22,148 82 - 22,230 Corporate Debt Securities 4,303 3 - 4,306 State and Municipal Bonds 1,275 7 - 1,282 Total marketable securities $ 46,019 $ 228 $ - $ 46,247
Schedule of Maturities of Debt Securities Available-for-sale	Maturities of debt securities classified as available-for-sale were as follows at December 31, 2020: Schedule of Maturities of Debt Securities Available-for-sale Accrued Net Carrying Fair Value Interest Amount Due within one year $ 31,438 $ 164 $ 31,602 Due after one year through five years 14,809 36 14,845 $ 46,247 $ 200 $ 46,447

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value Measurement of Assets and Liabilities	A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Schedule of Fair Value Measurement of Assets and Liabilities Fair Value Hierarchy June 30, 2021 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Treasury Bonds $ 10,482 $ 10,482 $ - $ - U.S. Government Notes 10,654 - 10,654 - Corporate Debt Securities 7,078 - 7,078 - State and Municipal Bonds 1,276 - 1,276 - Total $ 29,490 $ 10,482 $ 19,008 $ - Fair Value Hierarchy December 31, 2020 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Treasury Bonds $ 18,429 $ 18,429 $ - $ - U.S. Government Notes 22,230 - 22,230 - Corporate Debt Securities 4,306 - 4,306 - State and Municipal Bonds 1,282 - 1,282 - Total $ 46,247 $ 18,429 $ 27,818 $ -

Leasehold Improvements and Eq_2

Leasehold Improvements and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Leasehold Improvements and Equipment	Leasehold improvements and equipment, summarized by major category, consist of the following as of June 30, 2021 and December 31, 2020: Schedule of Leasehold Improvements and Equipment June 30, 2021 December 31, 2020 Lab equipment $ 1,443 $ 1,443 Leasehold improvements 878 878 Total 2,321 2,321 Less: accumulated depreciation and amortization 914 797 Leasehold improvements and equipment, net $ 1,407 $ 1,524

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued Expenses, summarized by major category, as of June 30, 2021 and December 31, 2020 consist of the following: Schedule of Accrued Expenses June 30, 2021 December 31, 2020 Payroll and incentives $ 619 $ 1,094 General and administrative expenses 249 280 Research and development expenses 1,055 778 Deferred revenue and other deferred liabilities * 840 643 Total $ 2,763 $ 2,795 * At June 30, 2021, there was an approximately $ 807 33 577 67

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Schedule of Maturity of Operating and Finance Leases Liabilities	The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases, excluding the Expansion Premises which the Company had not taken control of as of June 30, 2021, and finance leases as of June 30, 2021: Schedule of Maturity of Operating and Finance Leases Liabilities Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities Remainder of 2021 $ 314 $ 17 2022 645 19 2023 677 2 2024 710 - 2025 745 - 2026 - - Thereafter 1,458 - Total undiscounted operating lease payments $ 4,549 $ 38 Less: Imputed interest 1,074 - Present value of operating lease liabilities $ 3,475 $ 38 Weighted average remaining lease term in years 6.3 1.3 Weighted average discount rate 8.4 % 8.0 % The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases, excluding the Expansion Premises which the Company had not taken control of as of December 31, 2020, and finance leases as of December 31, 2020: Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities 2021 $ 685 $ 34 2022 645 19 2023 677 2 2024 710 - 2025 745 - Thereafter 1,458 - Total undiscounted operating lease payments $ 4,920 $ 55 Less: Imputed interest 1,224 - Present value of operating lease liabilities $ 3,696 $ 55 Weighted average remaining lease term in years 6.7 1.7 Weighted average discount rate 8.4 % 8.1 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Summary of Shareholders Equity Warrants Outstanding	Summary of Shareholders Equity Warrants Outstanding Shares Outstanding at December 31, 2019 5,397 Issued - Exercised (2,576 ) Tendered - Expired (1,493 ) Outstanding at December 31, 2020 1,328 * Outstanding at December 31, 2020 1,328 * Issued - Exercised (2 ) ** Tendered - Expired - Outstanding at June 30, 2021 1,326 *** * Weighted average exercise price for outstanding warrants is $ 0.55 ** Converted into approximately 1 thousand *** Weighted average exercise price for outstanding warrants is $ 0.54
Schedule of Anti-Diluted Securities Excluded FromComputation of Earning Per Share	Schedule of Anti-Diluted Securities Excluded FromComputation of Earning Per Share As of June 30, 2021 2020 Stock options 22,162 22,317 Preferred Stock and accrued dividend upon conversion - 9,104 Warrants 1,326 1,328 Total 23,488 32,749

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2021
Accumulated Other Comprehensive Income
Schedule of Components of Accumulated Other Comprehensive Income	The following table summarizes the changes in accumulated other comprehensive income by components during the three months ended June 30, 2021 and 2020: Schedule of Components of Accumulated Other Comprehensive Income Net Unrealized (Losses)/Gains on Available-for-Sale Securities Accumulated Other Comprehensive Balance, December 31, 2020 $ 228 $ 228 Net unrealized loss on securities available-for-sale (177 ) (177 ) Reclassifications to net loss - - Net current period other comprehensive loss (177 ) (177 ) Balance, June 30, 2021 $ 51 $ 51 Balance, December 31, 2019 $ (1 ) $ (1 ) Net unrealized gain on securities available-for-sale 482 482 Reclassifications to net loss (3 ) (3 ) Net current period other comprehensive income 479 479 Balance, June 30, 2020 $ 478 $ 478

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Equity Compensation Plan by Arrangements	The following table contains information about the Company’s stock plan at June 30, 2021: Schedule of Equity Compensation Plan by Arrangements Awards Awards Awards 2013 Equity Compensation Plan 36,952 * 27,127 ** 9,825 * Increased by 8,005 4 ** Includes both restricted stock grants and option grants
Schedule of Recognized Stock-Based Compensation	The Company recognized stock-based compensation expense (options and restricted share grants) in its condensed consolidated statements of operations as follows: Schedule of Recognized Stock-Based Compensation Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Research and Development $ 460 $ 358 $ 945 $ 1,180 General and Administrative 596 587 1,212 1,212 Total $ 1,056 $ 945 $ 2,157 $ 2,392
Schedule of Stock Option Activity	The following table summarizes the activity for Company’ stock options for the three months ended June 30, 2021: Schedule of Stock Option Activity Stock Options Outstanding at January 1, 2021 22,551 Granted 4,697 Exercised (1,063) Forfeited (2,681) Cancelled - Expired (1,341) Outstanding at June 30, 2021 22,163

Liquidity and Plan of Operati_2

Liquidity and Plan of Operations (Details Narrative) - USD ($)	Jun. 19, 2021	Jan. 14, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accumulated deficit			$ 118,098,218		$ 107,507,193
Net loss			(9,700,000)	$ (10,700,000)
Proceeds from public offering		$ 50,000,000	5,580,471	46,639,210
Cash and cash equivalents			30,352,359	14,904,000	12,432,481	$ 22,170,000
Marketable securities			29,490,430		$ 46,246,573
Restricted cash			$ 300,000
At The Market Sales Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from public offering				$ 5,600,000
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock in public offering, net of stock issuance costs, shares	8,436,000	32,300,000	3,023,147

Schedule of Cash, Cash Equivale

Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 30,352,359	$ 12,432,481	$ 14,904,000	$ 22,170,000
Restricted cash included in current/long term assets	336,000	336,000	486,000	586,000
Cash, cash equivalents and restricted cash in the statement of cash flows	$ 30,688,000	$ 12,768,000	$ 15,390,000	$ 22,756,000

Summary of Marketable Securitie

Summary of Marketable Securities (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 29,439	$ 46,019
Available-for-sale Securities, Gross Unrealized Gain	61	228
Available-for-sale Securities, Gross Unrealized Loss	(10)
Available-for-sale Securities	29,490	46,247
U.S. Treasury Bonds [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Available-for-sale Securities, Amortized Cost Basis	10,453	18,293
Available-for-sale Securities, Gross Unrealized Gain	29	136
Available-for-sale Securities, Gross Unrealized Loss
Available-for-sale Securities	10,482	18,429
U.S. Government Notes [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Available-for-sale Securities, Amortized Cost Basis	10,624	22,148
Available-for-sale Securities, Gross Unrealized Gain	31	82
Available-for-sale Securities, Gross Unrealized Loss	(1)
Available-for-sale Securities	10,654	22,230
Corporate Debt Securities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Available-for-sale Securities, Amortized Cost Basis	7,087	4,303
Available-for-sale Securities, Gross Unrealized Gain		3
Available-for-sale Securities, Gross Unrealized Loss	(9)
Available-for-sale Securities	7,078	4,306
State and Municipal Bonds [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Available-for-sale Securities, Amortized Cost Basis	1,275	1,275
Available-for-sale Securities, Gross Unrealized Gain	1	7
Available-for-sale Securities, Gross Unrealized Loss
Available-for-sale Securities	$ 1,276	$ 1,282

Schedule of Maturities of Debt

Schedule of Maturities of Debt Securities Available-for-sale (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Due within one year, fair value	$ 21,851	$ 31,438
Due within one year, accrued interest	122	164
Due within one year, net carrying amount	21,973	31,602
Due after one year through five years, fair value	7,639	14,809
Due after one year through five years, accrued interest	25	36
Due after one year through five years, net carrying amount	7,664	14,845
Debt Securities Available-for-sale, fair value	29,490	46,247
Debt Securities Available-for-sale, accrued interest	147	200
Debt Securities Available-for-sale, net carrying amount	$ 29,637	$ 46,447

Cash, Cash Equivalents, Restr_3

Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Marketable securities, unrealized gain loss	$ 85	$ 42	$ 177	$ 481
Net accumulated unrealized gain	$ 51		$ 51		$ 228

Schedule of Fair Value Measurem

Schedule of Fair Value Measurement of Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	$ 29,490	$ 46,247
Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	10,482	18,429
Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	19,008	27,818
Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
U.S. Treasury Bonds [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	10,482	18,429
U.S. Treasury Bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	10,482	18,429
U.S. Treasury Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
U.S. Treasury Bonds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
U.S. Government Notes [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	10,654	22,230
U.S. Government Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
U.S. Government Notes [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	10,654	22,230
U.S. Government Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
Corporate Debt Securities [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	7,078	4,306
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	7,078	4,306
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
State and Municipal Bonds [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	1,276	1,282
State and Municipal Bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
State and Municipal Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	1,276	1,282
State and Municipal Bonds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities

Schedule of Leasehold Improveme

Schedule of Leasehold Improvements and Equipment (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total	$ 2,321,000	$ 2,321,000
Less: accumulated depreciation and amortization	914,000	797,000
Leasehold improvements and equipment, net	1,406,748	1,523,950
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	1,443,000	1,443,000
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 878,000	$ 878,000

Leasehold Improvements and Eq_3

Leasehold Improvements and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 59	$ 58	$ 117	$ 115

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)		Jun. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Payroll and incentives		$ 619,000	$ 1,094,000
General and administrative expenses		249,000	280,000
Research and development expenses		1,055,000	778,000
Deferred revenue and other deferred liabilities *	[1]	840,000	643,000
Total		$ 2,762,736	$ 2,795,329
[1]	At June 30, 2021, there was an approximately $ 807 33 577 67

Schedule of Accrued Expenses _2

Schedule of Accrued Expenses (Details) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
CFF Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred liability	$ 807	$ 577
Genentech Feasibility Study Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue	$ 33	$ 67

Schedule of Maturity of Operati

Schedule of Maturity of Operating and Finance Leases Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Operating Lease Liabilities, Remainder of 2021	$ 314
Finance Lease Liabilities, Remainder of 2021	17
Operating Lease Liabilities, 2022	645
Finance Lease Liabilities, 2022	19
Operating Lease Liabilities, 2023	677
Finance Lease Liabilities, 2023	2
Operating Lease Liabilities, 2024	710
Finance Lease Liabilities, 2024
Operating Lease Liabilities, 2025	745
Finance Lease Liabilities, 2025
Operating Lease Liabilities, Thereafter	1,458
Finance Lease Liabilities, Thereafter
Total undiscounted operating lease payments	4,549
Total undiscounted finance lease payments	38
Operating Lease Liabilities, less: Imputed interest	1,074
Finance Lease Liabilities, less: Imputed interest
Present value of operating lease liabilities	3,475
Present value of finance lease liabilities	$ 38
Operating Lease Liabilities, weighted average remaining lease term in years	6 years 3 months 18 days
Finance Lease Liabilities, weighted average remaining lease term in years	1 year 3 months 18 days
Operating Lease Liabilities, weighted average discount rate	8.40%
Finance Lease Liabilities, weighted average discount rate	8.00%
Operating Lease [Member]
Lessee, Lease, Description [Line Items]
Operating Lease Liabilities, 2022		$ 685
Operating Lease Liabilities, 2023		645
Operating Lease Liabilities, 2024		677
Operating Lease Liabilities, 2025		710
Operating Lease Liabilities, 2026		745
Operating Lease Liabilities, Thereafter		1,458
Total undiscounted operating lease payments		4,920
Operating Lease Liabilities, less: Imputed interest		1,224
Present value of operating lease liabilities		$ 3,696
Operating Lease Liabilities, weighted average remaining lease term in years		6 years 8 months 12 days
Operating Lease Liabilities, weighted average discount rate		8.40%
Finance Lease [Member]
Lessee, Lease, Description [Line Items]
Finance Lease Liabilities, 2022		$ 34
Finance Lease Liabilities, 2023		19
Finance Lease Liabilities, 2024		2
Finance Lease Liabilities, 2025
Finance Lease Liabilities, 2026
Finance Lease Liabilities, Thereafter
Total undiscounted finance lease payments		55
Finance Lease Liabilities, less: Imputed interest
Present value of finance lease liabilities		$ 55
Finance Lease Liabilities, weighted average remaining lease term in years		1 year 8 months 12 days
Finance Lease Liabilities, weighted average discount rate		8.10%

Leases (Details Narrative)

Leases (Details Narrative)	Sep. 23, 2020USD ($)ft²	Nov. 01, 2013USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Leases [Abstract]
Lessee, operating lease, term of contract		7 years	10 years		10 years
Lessee, operating lease, option to extend					Some leases include purchase, termination or extension options for one or more years.
Lease monthly rent expense		$ 13,000
Increase of rent expenses		$ 14,000
Area of land | ft²	3,034
Operating lease extended term	seven years
Operating lease extension period	seven-year
Lease expense	$ 1,800,000		$ 204,000	$ 203,000	$ 407,000	$ 407,000
Operating lease right-of-use assets amortization expenses			116,000	120,000	243,000	238,000
Finance lease, interest expense			1,000	2,000	2,000	4,000
Finance lease right-of-use assets amortization expenses			$ 9,000	$ 19,000	$ 20,656	$ 41,678

Collaboration Agreements, Lic_2

Collaboration Agreements, Licenses and Other Research and Development Agreements (Details Narrative) - USD ($)	Dec. 12, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Nov. 19, 2020	Dec. 13, 2019
Entity Listings [Line Items]
Research and development expenses		$ 2,480,764	$ 3,410,237	$ 5,722,196	$ 7,497,120
Revenue				33,333
Genentech [Member]
Entity Listings [Line Items]
Revenue				33,000
Award Agreement [Member]
Entity Listings [Line Items]
Research and development expenses		547,000		971,000
Award Agreement [Member] | Accrued Expense And Other Current Liabilities [Member]
Entity Listings [Line Items]
Deferred liability		$ 807,000		$ 807,000		$ 650,000
Related receivable						577,000
Award Agreement [Member] | Cystic Fibrosis Foundation [Member]
Entity Listings [Line Items]
Therapeutics development award							$ 4,200,000
Proceeds from award						$ 484,249
Genentech Feasibility Study Agreement [Member] | Genentech [Member]
Entity Listings [Line Items]
Agreement description	Genentech shall pay the Company a total of $100 thousand for developing oral formulations of three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement.
Deferred revenue								$ 100,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Sale of net operating losses	$ 1.3	$ 1.1

Summary of Shareholders Equity

Summary of Shareholders Equity Warrants Outstanding (Details) - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2021		Dec. 31, 2020
Equity [Abstract]
Shares Outstanding, beginning	1,328,000	[1]	5,397,000
Shares Issued
Shares Exercised	(2,000)	[2]	(2,576,000)
Shares Tendered
Shares Expired			(1,493,000)
Shares Outstanding, ending	1,326,000	[3]	1,328,000	[1]
Number of securities exercised by warrants	1
[1]	Weighted average exercise price for outstanding warrants is $ 0.55
[2]	Converted into approximately 1 thousand
[3]	Weighted average exercise price for outstanding warrants is $ 0.54

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Shareholders Equity Warrants Outstanding (Details) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Number of warrant common stock converted	$ 0.54	$ 0.55

Schedule of Anti-Diluted Securi

Schedule of Anti-Diluted Securities Excluded FromComputation of Earning Per Share (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	23,488	32,749
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	22,162	22,317
Preferred Stock And Accrued Dividend Upon Conversion [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		9,104
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,326	1,328

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Jun. 19, 2021	Jun. 19, 2021	Jun. 19, 2020	Jan. 14, 2020	Jun. 19, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from Issuance Initial Public Offering				$ 50,000,000				$ 5,580,471	$ 46,639,210
Preferred stock, shares outstanding						0		0		4,361
Dividend description								(i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021.
Number of warrant to purchase of common stock						1,325,810		1,325,810
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion price per share						$ 0.50		$ 0.50
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion price per share						$ 0.75		$ 0.75
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number share issued upon conversion					8,000
Preferred stock converted	2,000	2,000
Preferred stock, shares outstanding						0		0		4,361
Merger Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from Issuance Initial Public Offering				$ 46,600,000
Underwritten Public Offering [Member] | Sales Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds from common stock								$ 5,600,000
BTIGLLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Average price per shares						$ 1.90		$ 1.90
Gross proceeds from common stock								$ 5,800,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of underwritten public offering of common stock		8,436,000		32,300,000				3,023,147
Share Price				$ 1.55
Number share issued upon conversion						8,436,000		8,722,000	50,000
Dividend shares						1,687,200	1,365,600	1,687,200	1,365,600
Common Stock [Member] | Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Dividend shares	1,687,200		1,365,600

Schedule of Components of Accum

Schedule of Components of Accumulated Other Comprehensive Income (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Accumulated Other Comprehensive Income
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance	$ 228,000	$ (1,000)
Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance	228,172	(1,000)
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized loss on securities available-for-sale	(177,000)	482,000
Accumulated Other Comprehensive (Loss)/Gain, Net unrealized loss on securities available-for-sale	(177,000)	482,000
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Reclassifications to net loss		(3,000)
Accumulated Other Comprehensive (Loss)/Gain, Reclassifications to net loss		(3,000)
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Other comprehensive income (loss)	(177,000)	479,000
Accumulated Other Comprehensive (Loss)/Gain, Other comprehensive gain	(177,000)	479,000
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Ending Balance	51,000	478,000
Accumulated Other Comprehensive (Loss)/Gain, Ending Balance	$ 51,243	$ 478,000

Schedule of Equity Compensation

Schedule of Equity Compensation Plan by Arrangements (Details) - 2013 Equity Compensation Plan [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards Reserved for Issuance	36,952	[1]
Awards Issued	27,127	[2]
Awards Available for Grant	9,825
[1]	Increased by 8,005 4
[2]	Includes both restricted stock grants and option grants

Schedule of Equity Compensati_2

Schedule of Equity Compensation Plan by Arrangements (Details) (Parenthetical) - shares shares in Thousands	May 08, 2014	Dec. 31, 2020	Jan. 02, 2020
Share-based Payment Arrangement [Abstract]
Increased shares of common stock outstanding			8,005
Percentage for common stock outstanding	4.00%	4.00%

Schedule of Recognized Stock-Ba

Schedule of Recognized Stock-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 1,056,000	$ 945,000	$ 2,156,941	$ 2,391,694
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	460,000	358,000	945,000	1,180,000
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 596,000	$ 587,000	$ 1,212,000	$ 1,212,000

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - Stock Options [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2021shares
Option Indexed to Issuer's Equity [Line Items]
Outstanding at January 1, 2021	22,551
Granted	4,697
Exercised	(1,063)
Forfeited	(2,681)
Cancelled
Expired	(1,341)
Outstanding at June 30, 2021	22,163

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($) $ in Thousands	May 08, 2014	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Option Indexed to Issuer's Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	4.00%					4.00%
Unrecognized share-based compensation		$ 28		$ 28
Share-based compensation weighted average period				3 months 18 days
Number of restricted stock awards granted				18,000	247,000
General and administrative expense		$ 28	$ 93	$ 57	$ 173
Unrecognized share-based compensation, shares		100,000		100,000
Stock Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Unrecognized share-based compensation		$ 9,400		$ 9,400
Share-based compensation weighted average period				2 years 9 months 18 days